Kristin Wohlschlagel, RN, is an experienced and compassionate nurse, specializing in Oncology and Hospice/Palliative care. She is well-versed in both conventional and alternative or integrative therapies. She has advanced knowledge in the use of medicinal cannabis for both symptom management as well as integrative care protocols for serious chronic diseases.
Kristin practices in many regions of the United States, and is frequently contacted for consultation from doctors and nurses around the world. She stays in close communication with worldwide cannabinoid and oncology researchers to monitor latest research findings and to provide these mostly preclinical researchers with valued “bed to bench” information about patient use and efficacy patterns. She welcomes contact from any healthcare professionals or researchers who are interested in discussion of these topics. She currently resides in Hawaii, but travels frequently to the mainland United States and abroad. She is available by phone, video calls as well as in-person presentations, and speaking engagements. She has collaborated with many nurses and physicians and specializes in caring for those patients with advanced cancer and/or autoimmune diseases.
Kristin Wohlschlagel, RN, has been certified in various specialties over her 14-year nursing career, including, but not limited to: Oncology Nurse Society Certification, Hospice and Palliative Nursing Certification (CHPN); Trauma Nurse Certification; as well as many of the available Medicinal Cannabis certification courses. She is an active member of the American Cannabis Nurses Association and the Oncology Nurses Society.
This presentation will include the case study of a child who was diagnosed in August, 2016 with Pre-B Cell ALL/AML and moderate/severe Graft Versus Host Disease. With the only remaining options being maintenance palliative chemotherapy or referral to hospice, the parents decided to seek support for the use of cannabis in the treatment of their daughter’s leukemia and GVHD and temporarily declined chemotherapy. Within two days of using cannabis extracts as directed by her pediatrician, her appetite, comfort and behavior began to improve. Within 30 days, her pulmonary symptoms had mostly resolved. The patient was determined to be in remission with full donor-marrow response, with testing done in October, 2017. These results were confirmed again in May, 2018, with testing of bone marrow biopsy, blood and CSF. She is described by her family as thriving, full of energy, and learning. She continues with cannabis medications and is monitored by her healthcare team, including oncologist, pediatrician and nurse. The poster discussion will also include information related to dosing, methods of administration, blood count monitoring, symptoms and symptom management. Discussion of leukemia biology, current treatments, preclinical and clinical research data and potential opportunities for cannabis therapy integrated into treatment protocols are welcomed. Potential benefits, adverse effects, challenges and potential clinical trial and research suggestions.
The authors efforts were self-funded and no conflicts of interest from any commercial funding sources are applicable.